BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:AGIOS PHARMACEUTICALS\, INC. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies AGIOS PHARMACEUTICALS\, INC.'s dr
 ugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07517133-10280@assetmemo.bio
DTSTAMP:20261121T004958Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Pyrukynd (Mitapivat): Phase 3 readout est. (NCT07517133)
DESCRIPTION:Pyrukynd (Mitapivat)\, phase 3.\nStudy: A Study to Investigate 
 the Efficacy\, Pharmacokinetics\, and Safety of Mitapivat in Pediatric Par
 ticipants With α- or β-Non-Transfusion-Dependent Thalassemia\nEstimated 
 primary completion: March 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/mitapivat#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07517133
URL:https://assetmemo.bio/drug/mitapivat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07506863-10280@assetmemo.bio
DTSTAMP:20261121T004958Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Pyrukynd (Mitapivat): Phase 3 readout est. (NCT07506863)
DESCRIPTION:Pyrukynd (Mitapivat)\, phase 3\, Transfusion-Dependent Beta Tha
 lassemia.\nStudy: A Study to Investigate the Efficacy\, Pharmacokinetics\,
  and Safety of Mitapivat in Pediatric Participants With Transfusion-Depend
 ent Alpha- or Beta-Thalassemia (α- or β-TDT)\nEstimated primary completi
 on: June 2029. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mitapi
 vat#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07506863
URL:https://assetmemo.bio/drug/mitapivat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07656415-10280@assetmemo.bio
DTSTAMP:20261121T004958Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Pyrukynd (Mitapivat): Phase 3 readout est. (NCT07656415)
DESCRIPTION:Pyrukynd (Mitapivat)\, phase 3\, Sickle Cell Disease.\nStudy: A
  Study to Investigate the Effect of Mitapivat on Transfusion Burden in Sub
 jects With Sickle Cell Disease (SCD)\nEstimated primary completion: August
  2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/mitapivat#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07656415
URL:https://assetmemo.bio/drug/mitapivat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
